Model Estimates Little Impact on US Payer Budgets by the Use of Selinexor, Bortezomib, Dexamethasone in Previously-Treated Multiple Myeloma

According to the results of a study published in ClinicoEconomics and Outcomes Research, the introduction of selinexor, bortezomib, and dexamethasone (XVd) for the treatment of patients with previously treated multiple myeloma (MM) presents a manageable budget impact for a private third-party payer and Medicare in the US.

Read the source article at Hematology Advisor
2021-07-12 15:18:39